

REMARKS


In view of the foregoing amendments and the following representations, allowance of the above-identified application is respectfully requested.

All the claims as originally filed, claims 1-11, have been canceled without prejudice. New claims 12-17 are submitted for consideration and are in the present application. No new matter is added by the newly presented claims. Support can be found in claims 1-11 as originally filed and in the specification on page 3, lines 26-29, page 4, lines 8-11 and 29-34, page 5, lines 12-14, 25-27, page 6, line 32 to page 7, line 25 and Example 6 found on pages 13-17.

Applicants respectfully submit that none of the references of record in the parent application disclose the unique method for forming an omeprazole pellet as recited in the pending claims. More specifically, none of the references of record in the parent application disclosed or suggested a method for forming an omeprazole pellet that consists of forming a core with about 10 weight percent or less of arginine or lysine and directly coating the core an enteric coating material which contains 5-50 weight percent of an inert processing aid. Further none of the references of record in the parent application disclose or suggest applying the enteric coating directly to the core using an organic based solvent as recited in new claim 13.

Based upon the foregoing amendments and representations,
Applicants respectfully submit that the claims in the present application are patentable.
Early and favorable action is earnestly solicited.

Respectfully submitted,



Martin P. Endres
Reg. No. 35,498

MAILING ADDRESS:
HEDMAN & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036-2601
(212) 302-8989